Associations of sNfL with clinico‐radiological measures in a large MS population
| Autor: | Elias S. Sotirchos, Kathryn C. Fitzgerald, Carol M. Singh, Matthew D. Smith, Maria Reyes‐Mantilla, Carrie M. Hersh, Megan H. Hyland, Ryan Canissario, Sarah B. Simmons, Georgina Arrambide, Xavier Montalban, Manuel Comabella, Robert T. Naismith, Min Qiao, Lauren B. Krupp, Jacqueline A. Nicholas, Katja Akgün, Tjalf Ziemssen, Richard Rudick, Elizabeth Fisher, Robert A. Bermel, Ellen M. Mowry, Peter A. Calabresi |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Sotirchos ES, Fitzgerald KC, Smith MD, Reyes-Mantilla M] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. [Singh CM] Biogen, Cambridge, Massachusetts, USA. [Hersh CM] Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, Nevada, USA. [Arrambide G, Montalban X, Comabella M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2022 |
| Předmět: |
células::estructuras celulares::espacio intracelular::citoplasma::estructuras citoplasmáticas::citoesqueleto::filamentos intermedios [ANATOMÍA]
General Neuroscience enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES] Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES] Esclerosi múltiple Filaments citoplasmàtics Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Cytoskeleton::Intermediate Filaments [ANATOMY] Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] Neurology (clinical) Cervell - Imatgeria Nervous System::Central Nervous System::Brain [ANATOMY] sistema nervioso::sistema nervioso central::encéfalo [ANATOMÍA] Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] |
| Zdroj: | Scientia |
| ISSN: | 2328-9503 |
| DOI: | 10.1002/acn3.51704 |
| Popis: | Esclerosi múltiple; Cadena lleugera de neurofilaments sèrics Esclerosis múltiple; Cadena ligera de neurofilamentos séricos Multiple sclerosis; Serum neurofilament light chain Objective Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. Methods Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high-throughput, scalable immunoassay. Results Elevated sNfL levels for age (sNfL-E) were found in 1238 MS participants (17.8%). Factors associated with sNfL-E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease-modifying therapy was associated with lower odds of sNfL-E. MS participants with sNfL-E exhibited worse neurological function (patient-reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short-term rates of whole brain atrophy in sNfL-E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL-E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age-normative sNfL Z-scores as a continuous variable. Interpretation Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking. Study funding was provided from the National Institutes of Health (K23NS117883 to E.S.S.; K01MH121582 to K.C.F.; U01NS111678 to P.A.C.), National Multiple Sclerosis Society (RG-1904-33834 to E.S.S.; RG-1904-33800 to P.A.C.), and Biogen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|